<DOC>
	<DOCNO>NCT02520752</DOCNO>
	<brief_summary>Drg-drug Interaction ( DDI ) study assess effect INC280 pharmacokinetics midazolam caffeine patient cMET-dysregulated advanced solid tumor</brief_summary>
	<brief_title>A DDI Study Assess Effect INC280 PK Midazolam Caffeine Patients With cMET-dysregulated Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patients must : advanced solid tumor confirm cMET dysregulation least one measurable lesion define RECIST 1.1. recover toxicity relate prior anticancer therapy adequate organ function ECOG performance status ( PS ) 0 1 Patients must : know hypersensitivity excipients INC280 benzodiazepine know intolerance hypersensitivity caffeine symptomatic central nervous system ( CNS ) metastases neurologically unstable presence history carcinomatous meningitis history another primary malignancy currently clinically significant currently require active intervention Clinically significant , uncontrolled heart disease , include QTcF ≥ 450 m ( male patient ) , ≥ 460 m ( female patient ) screen ECG Thoracic radiotherapy lung field ≤ 4 week prior start INC280 Major surgery within 4 week prior start INC280 Patients receive unstable increase dos corticosteroid . Impairment GI function GI disease may significantly alter absorption INC280 Patients receive consume , expect receive consume midazolam caffeinecontaining product ( e.g. , tea , coffee , cola ) , within 2 day prior Day 1 whole duration DDI phase ( i.e. , Day 2 Day 12 ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cMET , INC280 , caffeine , midazolam</keyword>
</DOC>